Pharmaceutical Policy in the UK

Adrian Kay

Research output: Contribution to journalArticlepeer-review

Abstract

For many years drug price regulation posed few public management problems. However, the overall NHS drugs budget has been increasing by almost 9% per annum over the past decade. Governments in the 1990s tried to control this growth by introducing new pharmaceutical policy instruments. This has led to an element of instability in the regulation of the pharmaceutical industry, which is affecting NHS financial programming, as well as R&D investment decisions by companies. This article recommends the creation of an office for drug regulation (an ‘OFDRUG’) to reintroduce stability into pharmaceutical policy.
Original languageEnglish
Pages (from-to)51-54
JournalPublic Money and Management
Volume21
Issue number4
DOIs
Publication statusPublished - 2001

Fingerprint

Dive into the research topics of 'Pharmaceutical Policy in the UK'. Together they form a unique fingerprint.

Cite this